Schizophrenia Research
Volume 78, Issue 1 , Pages 69-86 , 1 October 2005

The many faces of nitric oxide in schizophrenia. A review

  • Hans-Gert Bernstein

      Affiliations

    • Department of Psychiatry, University of Magdeburg, Leipziger Str.44, D-39120 Magdeburg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 392 67 14249; fax: +49 391 67 15223.
    • ,
  • Bernhard Bogerts

      Affiliations

    • Department of Psychiatry, University of Magdeburg, Leipziger Str.44, D-39120 Magdeburg, Germany
    • ,
  • Gerburg Keilhoff

      Affiliations

    • Institute of Medical Neurobiology, University of Magdeburg, Germany

Received 29 April 2005 ,Revised 24 May 2005 ,Accepted 24 May 2005.

References 

  1. Abbott LC, Nahm S-S. Neuronal nitric oxide synthase expression in cerebellar mutant mice. Cerebellum. 2004;3:141–151
  2. Acarin L, Peluffo H, Barbeito L, Castello B, Gonzales B. Astroglial nitration after postnatal excitotoxic damage: correlation with nitric oxide sources, cytoskeletal, apoptotic and antioxidant proteins. J. Neurotrauma. 2005;22:189–200
  3. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA, et al. Altered distribution of nictotin-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry. 1993;50:169–177
  4. Akbarian S, Viñuela A, Kim JJ, Potkin SG, Bunney WE, Jones EG. Distorted distribution of nicotinamide adenine dinucleotide-phosphate diaphorase neurons in temporal lobe of schizophrenica implies anomalous cortical development. Arch. Gen. Psychiatry. 1993;50:178–187
  5. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry. 1996;53:425–436
  6. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as aphysiopathological factor in neuropsychiatric disorders. In vivo. 2004;18:377–390
  7. Andreasen NC, Rezai K, Alliger R, Swayzell VW, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with Xenon-1333 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry. 1992;49:943–958
  8. Antunes F, Nunes C, Laranjinha J, Cadenas E. Redox interaction of nitric oxide with dopamine and its derivatives. Toxicology. 2005;208:207–212
  9. Averbukh ML, Kas'ko AF, Nikolenko ES, Rybas II. On the diagnostic significance of Black´s reaction in psychiatric patients. Lab. Delo. 1966;5:289–291
  10. Baba H, Suzuki T, Arai H, Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport. 2004;15:677–680
  11. Becker A, Paters B, Schröder H, Mann T, Hüther G, Grecksch G. Ketamine-induced changes in rat behavior: a possible animal model of schizophrenia. Prog. Neurop-sychopharmacol. Biol. Psychiatry. 2003;27:687–700
  12. Beckman JS, Koppenol WH. Nitric oxide, superoxide, peroxynitrite: the good, the bad, the ugly. Am. J. Physiol. 1996;271:C424–C432
  13. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 2001;25:1–27
  14. Ben-Shachar D, Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 2004;59:273–296
  15. Bernstein H-G, Stanarius A, Baumann B, Henning H, Krell D, Danos P, et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressed patients and schizophrenics. Neuroscience. 1998;83:867–875
  16. Bernstein H-G, Keilhoff G, Seidel B, Stanarius A, Huang PL, Fishman MC, et al. Expression of hypothalamic peptides in mice lacking neuronal nitric oxide synthase: reduced beta-END immunoreactivity in the arcuate nucleus. Neuroendocrinology. 1998;68:403–411
  17. Bernstein H-G, Grecksch G, Becker A, Höllt V, Bogerts B. Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport. 1999;10:2307–2311
  18. Bernstein H-G, Jirikowski GF, Heinemann A, Baumann B, Hornstein C, Danos P, et al. Low and infrequent expression of nitric oxide synthase/NADPH diaphorase in neurons of the human supraoptic nucleus: a histochemical study. J. Chem. Neuroanat. 2000;20:177–183
  19. Bernstein H-G, Krell D, Braunewell K-H, Baumann B, Gundelfinger ED, Diekmann S, et al. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J. Neurocytol. 2001;30:661–670
  20. Bernstein H-G, Heinemann A, Krell D, Mawrin C, Bielau H, Danos P, et al. Further immunohistochemical evidence for impaired NO signaling in the hypothalamus of depressed patients. Ann. N. Y. Acad. Sci. 2002;973:91–93
  21. Bernstein H-G, Brisch R, Ogunlade V, Heinemann A, Baumann B, Arendt T, et al. Detection of nitric oxide synthase (NOS) immunoreactive neurons in the human septal area: a matter of method. J. Chem. Neuroanat. 2004;27:247–250
  22. Bernstein H-G, Heinemann A, Bogerts B. Electro-convulsive therapy, nitric oxide and HPA axis: a closer look at human hypothalamus. Med. Hypotheses. 2004;62:158–159
  23. Bernstein, H.-G., Heinemann, A., Krell, D., Dobrowolny, H., Bielau, H., Keilhoff, G., Bogerts, B., in press. Hypothalamic nitric oxide synthase in affective disorder: Focus on the suprachiasmatic nucleus. Cell. Mol. Biol.
  24. Birch RE, Polmar SH. Pharmacological modification of immunoregulatory Tlymphocytes: I. Effect of adenosine, H1 and H2 histamine agonists upon Tlymphocyte regulation of B lymphocyte differentiation in vitro. Clin. Exp. Immunol. 1982;48:218–230
  25. Bird DC, Bujas-Bobanovic M, Robertson HA, Durson SA. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology. 2001;155:299–309
  26. Black MD, Selk DE, Hitchcock JM, Wettstein JG, Sörensen SM. On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology. 1999;38:1299–1306
  27. Black MD, Simmonds J, Senyah Y, Wettstein JG. Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology. 2002;42:414–420
  28. Blaise GA, Gauvin D, Gangal M, Authier S. Nitric oxide, cell signaling and cell death. Toxicology. 2005;208:177–192
  29. Blum-Degen D, Heinemann T, Lan J, Pedersen V, Leblhuber P, Riederer P, et al. Characterization and regional distribution of nitric oxide synthase in the human brain during normal aging. Brain Res. 1999;834:128–135
  30. Boehning D, Snyder SH. Novel neural modulators. Annu. Rev. Neurosci. 2003;26:105–131
  31. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Sci. 2001;11:66–75
  32. Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitric oxides mediate neuronal cell death. Brain Res. 1992;587:250–256
  33. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U. S. A. 1990;87:682–685
  34. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron. 1992;8:3–11
  35. Brenman FE, Bredt DS. Synaptic signaling by nitric oxide. Curr. Opin. Neurobiol. 1997;7:374–378
  36. Brzustowicz LM, Siomne J, Mohseni P, Hayter JE, Hodgkinson KA, Chow EW, et al. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am. J. Hum. Genet. 2004;74:1057–1063
  37. Bujas-Bobanovic M, Robertson HA, Dursun SM. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencycldine-induced effects in rats. Eur. J. Pharmacol. 2000;409:57–65
  38. Bul'ba PA, Kas'ko AF, Averbukh ML, Nikolenko ES. Peculiarities of the Black reaction and white phenomenon in mental patients. Lab. Delo. 1968;6:350–352
  39. Buttenschon HN, Mors O, Ewald H, McQuillin A, Kalsi G, Lawrence J, et al. No association between a neuronal nitric oxide synthase (NOS1) gene polymorphism on chromosome 12q24 and bipolar disorder. Am. J. Med. Genet. B. 2004;124:73–75
  40. Candido CL, Rommey DM. Depression in paranoid and nonparanoid schizophrenic patients compared with major depressive disorder. J. Affect. Disord. 2002;70:261–271
  41. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol. Psychiatry. 2004;56:129–134
  42. Christopherson KS, Hillier BJ, Lim WA, Bredt DS. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 1999;274:27467–27473
  43. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am. J. Psychiatry. 2003;160:1100–1109
  44. Condray R, Glasgow AG. The relationship between membrane pathology and language disorder in schizophrenia. Prostaglandins Leukot. Essent. Fat. Acids. 2003;69:449–460
  45. Cook, C., 1996. Neurologic and psychiatric treatment with inhibitors of brain nitric oxide synthase. U.S. Patent # 5,527,825 http.//pharmalicensing.com/licensing/displicopp/150.
  46. Corcoran C, Walker E, Huot R, Mittal V, Tessnr K, Kestler L, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003;29:671–692
  47. Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, et al. A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit. Rev. Neurobiol. 2004;16:1–23
  48. Culotta E, Koshland EDE. NO news is good news. Science. 1992;258:1862–1865
  49. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun. 1995;212:375–380
  50. Das I, Khan NS, Hirsch SR. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci. Lett. 1996;215:209–211
  51. Das I, Ramchand CN, Gliddon A, Hirsch SR. Nitric oxide, free radicals and polyamines may have a role in membrane pathology of schizophrenia. Neuropsychobiology. 1998;37:65–67
  52. Das UN. Can memory be improved? A discussion on the role of ras, GABA, acetylcholine, NO, insulin, TNF-alpha, and long-chain polyunsaturated fatty acids in memory formation and consolidation. Brain Dev. 2003;25:251–261
  53. Dawson TM, Snyder SH. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J. Neurosci. 1994;14:5147–5159
  54. Del Bel EA, da Silva CA, Guimarães FS, Bermuda-Echeverry M. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur. J. Pharmacol. 2004;485:175–181
  55. Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner L, Morn CB, et al. 7-nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviours in mice. Neuropsychopharmacology. 1996;15:37–43
  56. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg P, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin. Neuropharmacol. 1997;20:357–363
  57. Di Giacomo C, Sorrenti V, Salerno L, Cardile V, Guerriera , Siracusa MA, et al. Novel inhibitors of neuronal nitric oxide synthase. Exp. Biol. Med. 2003;228:486–490
  58. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal nitric oxide synthase expression in developing and adult human brain. J. Neuropathol. Exp. Neurol. 1999;58:12–21
  59. Doyle CA, Slater P. Application of [3H] L-NG-nitro-arginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Neurosci. Lett. 1995;202:49–52
  60. Dracheva S, McCurjk SR, Haroutunian V. mRNA expression of AMPA Receptor binding proteins in the cerebral cortex of elderly schizophrenics. J. Neurosci. Res. 2005;79:868–878
  61. Drapier JC, Hibbs JB. Differentiation of murine macrophages to express non-specific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J. Immunol. 1988;140:2238–2829
  62. Eastwood SL, Harrison PJ. Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Mol. Psychiatry. 2003;8:821–831
  63. Egberongbe YI, Gentleman SM, Falkai P, Bogerts B, Polak JM, Roberts GW. The distribution of nitric oxide synthase immunoreactivity in human brain. Neuroscience. 1994;59:561–578
  64. Elibol B, Söylemezoglu F, Ünal I, Fujii M, Hirt L, Huang PL, et al. Nitric oxide is involved in ischemia-induced apoptosis in brain: a study in neuronal nitric oxide synthase deficient null mice. Neuroscience. 2001;105:79–86
  65. Ende G, Hubrich P, Walter S, Weber-Fahr W, Kammerer N, Braus DF, et al. Further evidence for altered cerebellar integrity in schizophrenia. Am. J. Psychiatry. 2005;162:790–792
  66. Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci. 2004;27:283–289
  67. Fang M, Jaffrey SR, Sawa A, Ye K, Luo X, Snyder SH. Dextras 1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron. 2000;28:183–193
  68. Fatemi SH, Quadra AE, El-Fakahany EE, Sidwell RW, Thuras P. Prenatal viral infection causes alterations in NOS expression in developing mouse brains. Neuroreport. 2000;11:1493–1496
  69. Fernandez-Vizarra RJ, Castro-Blanco S, Ventura ML, Nieto M, Gomez-Isla T, Martinez-Murillo R, et al. Nitric oxide in the cerebral cortex of amyloid precursor protein in (SW) Tg2576 transgenic mice. Neuroscience. 2004;128:73–89
  70. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. A, J. Physiol. 2003;284:R1–R12
  71. Freedman R, Adams CE, Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology interneurons in schizophrenia. J. Chem. Neuroanat. 2000;20:299–306
  72. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376
  73. Galea E, Feinstein DI. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J. 1999;13:2125–2137
  74. Garcia-Hill E, Biedermann JA, Chambers T, Skinner RD, Mrak RE, Husain M, et al. Mesopontine neurons in schizophrenia. Neuroscience. 1995;66:321–335
  75. Gibbs SM. Regulation of neuronal proliferation and differentiation by nitric oxide. Mol. Neurosci. 2003;27:107–120
  76. Giraldi-Guimarães , Bittencourt-Navarrete EE, Mendez-Oter RC. Expression of neuronal nitric oxide synthase in the developing superficial layers of rat superior colliculus. Braz. J. Med. Biol. Res. 2004;37:869–877
  77. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu. Rev. Neurosci. 1995;57:737–769
  78. Hara H, Waeber PL, Huang PL, Fujii M, Fishman MC, Moskowitz MA. Brain distribution of nitric oxide synthase in neuronal and endothelial cells of nitric oxide synthase mutant mice using [3 H]–L–Nω–nitro-arginine autoradiography. Neuroscience. 1996;75:881–890
  79. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122:593–624
  80. Hemish J, Nakaya N, Mittal V, Enikolopov G. Nitric oxide activates diverse signaling pathways to regulate gene expression. J. Biol. Chem. 2003;278:42321–42329
  81. Herken H, Uz E, Özyurt H, Akyol Ö. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr. Res. 2001;52:289–290
  82. Ho BC, Mola C, Andreasen NC. Cerebellar dysfunction in neuroleptic naive schizophrenia patients: clinical, cognitive, and neuroanatomic correlates of cerebellar neurologic signs. Biol. Psychiatry. 2004;55:1146–1153
  83. Hobbs AJ, Ignarro LJ. Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol. 1996;269:134–148
  84. Iwahashi K, Yoneyama H, Ohnishi T, Nakamura K, Miyatake R, Suwaki H, et al. Haloperidol inhibits neuronal nitric oxide synthase activity by preventing electron transfer. Neuropsychobiology. 1996;33:76–79
  85. Johansson C, Kackson DM, Zhang J, Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol. Biochem. Behav. 1995;52:649–654
  86. Judas M, Sestan N, Kostovic I. Nitrinergic neurons in the developing and adult human telencephalon: transient and permanent patterns of expression in comparison to other mammals. Microsc. Res. Tech. 1999;45:401–419
  87. Karolewicz B, Szebeni K, Stockmeier CA, Konick L, Overholser JC, Jurjus G, et al. Low nNOS protein in the locus coeruleus in major depression. J. Neurochem. 2004;91:1057–1066
  88. Karson CN, Garcia-Rill E, Biedermann J, Mrak RE, Husain MM, Skinner RD. The brain stem reticular formation in schizophrenia. Psychiatry Res. 1991;40:31–48
  89. Karson CN, Griffin WST, Mrak RE, Husain M, Dawson TM, Snyder SH, et al. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol. Chem. Neuropathol. 1996;27:275–284
  90. Kawakami S, Ichikawa M, Yokosuka M, Tsukamura H, Maeda K. Glial and neuronal localization of the neuronal nitric oxide synthase immunoreactivity in the median eminence of female rats. Brain Res. 1998;789:322–326
  91. Keilhoff G, Seidel B, Noack H, Stanek D, Wolf G. Patterns of nitric oxide synthase at the messenger RNA and protein levels during early rat brain development. Neuroscience. 1996;75:1193–1201
  92. Keilhoff G, Seidel B, Reiser M, Stanarius A, Huang PL, Bogerts B, et al. Lack of neuronal NOS has consequences for the expression of POMC and POMC-derived peptides in the mouse pituitary. Acta Histochem. 2001;103:397–412
  93. Keilhoff G, Wolf G, Bernstein H-G. Altered laminar distribution of hippocampal zinc in mutant mice lacking neuronal nitric oxide synthase. A histochemical study. Neurosci. Lett. 2001;305:173–176
  94. Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein H-G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience. 2004;126:591–598
  95. Keilhoff G, Bernstein H-G, Becker A, Grecksch G, Wolf G. Increased neurogenesis in a rat ketamine model of schizophrenia. Biol. Psychiatry. 2004;56:317–322
  96. Kim WK, Choi YB, Rayudu PV, Das P, Asaad W, Arnelle DR, et al. Attenuation of NMDA receptors and neurotoxicity by nitroxyl anion. NO-. Neuron. 1999;24:461–469
  97. Kirchner L, Weitzdorfer R, Hoeger H, Uri A, Schmidt P, Engelmann M, et al. Impaired cognitive performances in neuronal nitric oxide synthase knockout mice is associated with hippocampal protein derangements. Nitric Oxide. 2004;11:316–330
  98. Kiss JP, Vizi ES. Nitric oxide: A novel link between synaptic and nonsynaptic transmission. Trends Neurosci. 2001;24:211–215
  99. Klamer D, Engel JA, Svensson L. The neuronal nitric oxide synthase inhibitor, N-omega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur. J. Pharmacol. 2004;503:103–107
  100. Klamer D, Engel JA, Svensson L. Phencyclidine-induced behavior in mice prevented by methylene blue. Basic Clin. Pharmacol. Toxicol. 2004;94:65–72
  101. Klamer D, Zhang J, Engel JA, Svensson L. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behav. Brain Res. 2005;159:95–103
  102. Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J. Immunol. 1986;137:3189–3194
  103. Lau YS, Petroske E, Meredith GE, Wang JQ. Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats. Neuropharmacology. 2003;45:986–994
  104. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 1999;43:542–548
  105. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005;6:312–324
  106. Liou Y-J, Tsai S-J, Hong C-J, Liao D-L. Association analysis for the CA repeat polymorphism of the neuronal nitric oxide (NOS1) gene and schizophrenia. Schizophr. Res. 2003;65:57–59
  107. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 2004;29:282–286
  108. Lipska BK, Jaskiw GE, Chrastusta S, Karoum F, Weinberger DR. Ibotenic lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res. 1992;585:1–6
  109. Lüth H-J, Münch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res. 2002;953:135–143
  110. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996;19:1–17
  111. Mai JK, Berger K, Sofroniew MV. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J. Hirnforsch. 1993;34:133–154
  112. Mantelas A, Stamatakis A, Kazanis I, Philippidis H, Stylianopoulous F. Control of neuronal nitric oxide synthase and brain-derived neurotrophic factor levels by GABA-A receptors in developing rat cortex. Brain Res. Dev. Brain Res. 2003;145:185–195
  113. Mawrin C, Kirches E, Krause G, Schneider-Stock R, Bogerts B, Vorwerk CK, et al. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci. Lett. 2004;357:111–114
  114. Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci. 1997;22:477–481
  115. McQuillen PS, Ferriero DM. Selective vulnerability in the developing central nervous system. Pediatr. Neurol. 2004;30:227–235
  116. Mungrue IN, Bredt DS. nNOS at a glance: implications for brain and brawn. J. Cell Sci. 2004;117:2627–2629
  117. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls and controls. Cell. 1994;78:915–918
  118. Nel A, Harvey BH. Haloperidol-induced dyskinesia associated with striatal NO synthase inhibition: reversal with olanzapine. Behav. Pharmacol. 2003;14:251–255
  119. Noack H, Possel H, Rethfeldt C, Keilhoff G, Wolf G. Peroxnitrite mediated damage and lowered superoxide tolerance in primary cortical glial cultures after induction of the inducible isoform of NOS. Glia. 1999;28:13–24
  120. Northoff G, Richter A, Bermpohl F, Grimm S, Martin E, Marcar VL, et al. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr. Res. 2005;72:235–248
  121. Okada D, Yap CC, Kojima H, Kikuchi K, Nagano T. Distinct glutamate receptors govern differential levels of nitric oxide production in a layer-specific manner in the rat cerebellar cortex. Neuroscience. 2004;125:461–472
  122. Packer MA, Stasiv Y, Benraiss A, Chmielnicki E, Grinberg A, Westphal H, et al. Nitric oxide negatively regulates mammalian adult neurogenesis. Proc. Natl. Acad. Sci. U. S. A. 2003;100:9566–9571
  123. Palacios M, Padron J, Glaria L, Rojas A, Delgado R, Knowles R, et al. Chlorpromazine inhibits both the constitutive nitric oxide synthase and the induction of nitric oxide synthase after LPS challenge. Biochem. Biophys. Res. Commun. 1993;196:280–286
  124. Pepicelli O, Brescia A, Gherzi E, Reiteri M, Fedele E. GABA(A), but not NMDA, receptors modulate in vivo NO-mediated cGMP synthesis in rat cerebral cortex. Neuropharmacology. 2004;46:480–489
  125. Pögün S, Kuhar MJ. Nitric oxide inhibits [3H] dopamine uptake. Brain Res. 1994;641:83–91
  126. Pomper MG, Musachio JL, Scheffel U, MacDonald JE, McCarthy DJ, Reif DW, et al. Radiolabeled neuronal nitric oxide synthase inhibitors: synthesis, in vivo evaluation, and primate PET studies. J. Nucl. Med. 2000;41:1417–1425
  127. Pou S, Keaton L, Surichamon T, Frigillana P, Rosen GM. Can nitric oxide be trapped by nitrone and nitrose compounds?. Biochim. Biophys. Acta. 1994;1201:118–124
  128. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT-J, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry. 2004;9:684–697
  129. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJ, Swaab DF. Increased number of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nuclei of depressed patients. Neuroendocrinology. 1994;60:436–444
  130. Ramirez J, Garnica R, Boll M-C, Montes S, Rios C. Low concentration of nitrite and nitrate in cerebrospinal fluid from schizophrenic patients; a pilot study. Schizophr. Res. 2004;86:357–361
  131. Ranjekar PK, Himnge A, Hedge MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121:109–122
  132. Roberts RC, Roche JK, Conley RR. Synaptic differences in the post- mortem striatum of subjects with schizophrenia: a stereological and ultrastructural analysis. Synapse. 2005;56:185–197
  133. Rosen Y, Reznik I, Sluvis A, Kaplan D, Mester R. The significance of the nitric oxide in electro-convulsive therapy: a proposed neurophysiological mechanism. Med. Hypotheses. 2003;60:424–429
  134. Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug-naive patients with schizophrenia. Psychoneuroendocrinology. 2004;29:4065–4070
  135. Russwurm M, Koesling D. Guanyl cyclase: NO hits its target. Biochem. Soc. Symp. 2004;71:51–63
  136. Salerno I, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr. Pharm. Res. 2002;8:177–200
  137. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999;284:1845–1848
  138. Savas HA, Herken H, Yurekli M, Uz E, Tutkun H, Zoroğlu SS, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology. 2002;45:57–61
  139. Selley ML. Increased (E)-4-hydroxy-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J. Affect. Disord. 2004;80:249–254
  140. Shinkai T, Ohmori O, Hori H, Nakamura J. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol. Psychiatry. 2002;7:560–563
  141. Shinkai T, Ohmori O, Matsumoto C, Hori H, Kennedy JL, Nakamura J. Genetic association analysis of neuronal nitric oxide gene polymorphism with tardive dyskinesia. Neuromolec. Med. 2004;5:163–170
  142. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002;1:232–241
  143. Snico CR, Portillo F, Gonzalez-Forero D, Moreno-Lopez B. Nitric oxide- directed synaptic remodeling in the adult mammal CNS. J. Neurosci. 2005;25:1448–1458
  144. Snyder SH, Bredt DS. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 1991;12:125–128
  145. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenic patients. Psychopharmacology. 2001;158:140–145
  146. Stanarius A, Seidel B, Wolf G. Neuronal nitric oxide synthase in the vasculature of the rat brain: an immunohistochemical study using the tyramine signal amplification technique. J. Neurocytol. 1998;27:731–736
  147. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury- induced inflammation and cytokine expression in the nervous system. Adv. Exp. Med. Biol. 2002;513:87–113
  148. Suzuki E, Nakaki T, Shintai F, Kanba S, Miyaoka H. Antopsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain. Nuerosci. Lett. 2002;333:217–219
  149. Suzuki E, Nakaki T, Nakamura M, Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J. Psychiatr. Neurosci. 2003;28:288–292
  150. Taneli F, Piridar Ş, Akdeniz F, Uyanik BS, Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch. Med. Res. 2004;35:401–405
  151. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide. 2002;7:297–300
  152. Tohgi H, Abe T, Yamazaki T, Murata C, Isobe C, Ishizaki E. The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimer's disease and vascular dementia of Biswanger type and multiple small infarct type. J. Neural Transm. 1998;105:1238–1291
  153. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004;67:269–275
  154. Vincent SR, Johansson O, Skirboll L, Hökfelt T. Coexistence of somatostatin- and avian pancreatic polypeptide-like immunoreactivities in striatal neurons which are selectively stained for NADPH-diaphorase activity. Adv. Biochem. Psychopharmacol. 1982;33:453–462
  155. Vleeming W, Rambali B, Opperhuizen A. The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob. Res. 2002;4:313–318
  156. Wang YC, Liou YJ, Liao DL, Bai YM, Lin CC, Yu SC, et al. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J. Neural Transm. 2004;111:623–629
  157. Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 2003;959:128–134
  158. Wiklund NP, Cellek S, Leone AM, Iversen HH, Gustafson LE, Brundin L, et al. Visualisation of nitric oxide released by nerve stimulation. J. Neurosci. Res. 1997;47:224–232
  159. Wiley JL, Golden KM, Bowen SE. Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats. Eur. J. Pharmacol. 1997;328:125–130
  160. Xing G, Chavko M, Zhang L-X, Yang S, Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr. Res. 2002;58:21–30
  161. Yanik M, Vural H, Kocyiğit , Tutkun H, Zoroğlu , Herken H, et al. Is the arginine–nitric oxide pathway involved in the pathogenesis of schizophrenia?. Neuropsychobiology. 2003;47:61–65
  162. Yanik M, Vural H, Tutkun H, Zoroğlu SS, Savas HA, Herken H, et al. The role of the arginine–nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur. Arch., Psychiatry Clin. Neurosci. 2004;254:43–47
  163. Yao JK, Leonard SS, Reddy RD. Increased nitric oxide radicals in post-mortem brains from schizophrenic patients. Schizophr. Res. 2001;49:58
  164. Yu YW, Chen TJ, Wang YC, Liou YL, Hong CJ, Tsai SJ. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluorexetine response. Neuropsychobiology. 2003;47:137–140
  165. Zheng Y, Li H, Quin W, Duan Y, Xiao Y, Li C, et al. Association of the carboxy-I-terminal PDZ ligand of the neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochem. Biophys. Res. Commun. 2005;328:809–815
  166. Zoroğlu SS, Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, et al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J. Psychiatr. Res. 2002;36:309–315

PII: S0920-9964(05)00210-0

doi: 10.1016/j.schres.2005.05.019

Schizophrenia Research
Volume 78, Issue 1 , Pages 69-86 , 1 October 2005

Article Tools

* Image Usage & Resolution